Phibro Animal Health Corporation (PAHC) Q4 2026 Earnings Call Transcript
Phibro Animal Health Corporation (PAHC) Q4 2026 Earnings Call Transcript
Seeking Alpha8/27/2026Neutral
PAHC
Phibro Animal Health CorporationNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$1.55B
P/E Ratio
15.74
EPS
$2.43
Beta
0.47
52W High
$59.64
52W Low
$28.04
50-Day MA
$34.85
200-Day MA
$41.86
Dividend Yield
1.24%
Profit Margin
6.57%
Forward P/E
13.83
PEG Ratio
1.68
About Phibro Animal Health Corporation
Phibro Animal Health Corporation develops, manufactures and supplies a range of mineral nutrition and animal health products for livestock primarily in the United States. The company is headquartered in Teaneck, New Jersey.
Fundamentals
| Revenue (TTM) | $1.52B |
| Gross Profit (TTM) | $505.97M |
| EBITDA | $244.23M |
| Operating Margin | 10.60% |
| Return on Equity | 29.70% |
| Return on Assets | 8.48% |
| Revenue/Share (TTM) | $37.44 |
| Book Value | $9.50 |
| Price-to-Book | 4.07 |
| Price-to-Sales (TTM) | 1.02 |
| EV/Revenue | 1.498 |
| EV/EBITDA | 9.76 |
| Quarterly Earnings Growth (YoY) | 24.60% |
| Quarterly Revenue Growth (YoY) | 4.80% |
| Shares Outstanding | $21.11M |
| Float | $20.91M |
| % Insiders | 0.87% |
| % Institutions | 103.80% |
Historical Volatility
HV 10-Day
39.15%
HV 20-Day
30.49%
HV 30-Day
32.57%
HV 60-Day
32.37%
HV Rank
8.3%
Volatility is currently expanding
Analyst Ratings
Consensus ($44.00 target)
1
Strong Buy3
Hold1
Strong SellLatest News
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2026 and provided its financial guidance for the fiscal year ending June 30, 2027. Highlights for the three months ended June 30, 2026 (compared to the three months ended June 30, 2025) – Net sales of $396.7 million, an increase of $18.1 million, or 5% – Net income of $21.7 million, an increase of $4.5.
Business Wire8/26/2026Neutral
Phibro (PAHC) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
Besides Wall Street's top-and-bottom-line estimates for Phibro (PAHC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Zacks Investment Research8/21/2026Neutral
Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2026 Results
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its fourth quarter and fiscal year 2026 financial results on Wednesday, August 26, 2026, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 27, 2026, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be availab.
Business Wire8/19/2026Neutral
PAHC vs. SYK: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two companies is the best option for those looking for undervalued stocks?
Zacks Investment Research7/27/2026Positive
PAHC or LZAGY: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Lonza Group Ag (LZAGY). But which of these two stocks is more attractive to value investors?
Zacks Investment Research7/9/2026Positive
PAHC vs. SYK: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two companies is the best option for those looking for undervalued stocks?
Zacks Investment Research6/22/2026Positive
What Makes Phibro (PAHC) a New Buy Stock
Phibro (PAHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research6/17/2026Positive
PAHC vs. SYK: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical - Products sector might want to consider either Phibro Animal Health (PAHC) or Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
Zacks Investment Research6/3/2026Positive
Implied Volatility Surging for Phibro Stock Options
Investors need to pay close attention to PAHC stock based on the movements in the options market lately.
Zacks Investment Research5/29/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PAHC and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026